564 related articles for article (PubMed ID: 16144528)
21. Dendritic cell vaccines for the treatment of prostate cancer.
Lehrfeld TJ; Lee DI
Urol Oncol; 2008; 26(6):576-80. PubMed ID: 18996314
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy of metastasis.
Dallal RM; Lotze MT
Surg Oncol Clin N Am; 2001 Apr; 10(2):433-47, xi. PubMed ID: 11382596
[TBL] [Abstract][Full Text] [Related]
23. [Changes of dendritic cells in prostate cancer and dendritic cell-based immunotherapy].
Qi SY; Wang M; Xu Y
Zhonghua Nan Ke Xue; 2007 May; 13(5):453-6. PubMed ID: 17569266
[TBL] [Abstract][Full Text] [Related]
24. Dendritic-cell vaccination for prostate cancer.
Thomas-Kaskel AK; Veelken H
Immunotherapy; 2009 Jan; 1(1):63-72. PubMed ID: 20635974
[TBL] [Abstract][Full Text] [Related]
25. [Pilot trial of vaccines based on autologous dendritic cells loaded in vitro with tumor antigens in the treatment of cancer of the urinary bladder].
Shoua AB; Sergienco NF; Sitnikov NV; Chkadua GZ
Urologiia; 2008; (5):54-7. PubMed ID: 19069498
[TBL] [Abstract][Full Text] [Related]
26. Recent advances and hurdles in melanoma immunotherapy.
Jandus C; Speiser D; Romero P
Pigment Cell Melanoma Res; 2009 Dec; 22(6):711-23. PubMed ID: 19735459
[TBL] [Abstract][Full Text] [Related]
27. Future directions in bladder cancer immunotherapy: towards adaptive immunity.
Smith SG; Zaharoff DA
Immunotherapy; 2016; 8(3):351-65. PubMed ID: 26860539
[TBL] [Abstract][Full Text] [Related]
28. Dendritic cells: tools and targets for antitumor vaccination.
den Brok MH; Nierkens S; Figdor CG; Ruers TJ; Adema GJ
Expert Rev Vaccines; 2005 Oct; 4(5):699-710. PubMed ID: 16221071
[TBL] [Abstract][Full Text] [Related]
29. Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects.
Minev BR; Guo F; Gueorguieva I; Kaiser HE
In Vivo; 2002; 16(6):405-15. PubMed ID: 12494883
[TBL] [Abstract][Full Text] [Related]
30. Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers.
Schott M
Endocr Relat Cancer; 2006 Sep; 13(3):779-95. PubMed ID: 16954430
[TBL] [Abstract][Full Text] [Related]
31. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in immunotherapy for human glioma.
Carpentier AF; Meng Y
Curr Opin Oncol; 2006 Nov; 18(6):631-6. PubMed ID: 16988586
[TBL] [Abstract][Full Text] [Related]
33. Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells.
Naoe M; Ogawa Y; Takeshita K; Morita J; Iwamoto S; Miyazaki A; Yoshida H
Int J Urol; 2007 Jun; 14(6):532-8; discussion 538. PubMed ID: 17593099
[TBL] [Abstract][Full Text] [Related]
34. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.
Suttmann H; Riemensberger J; Bentien G; Schmaltz D; Stöckle M; Jocham D; Böhle A; Brandau S
Cancer Res; 2006 Aug; 66(16):8250-7. PubMed ID: 16912205
[TBL] [Abstract][Full Text] [Related]
35. Role of animal models in understanding intravesical therapy with bacille Calmette-Guérin.
Ratliff TL
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S106-8. PubMed ID: 11010834
[TBL] [Abstract][Full Text] [Related]
36. Dendritic cell-based cancer immunotherapies.
Fujii S; Takayama T; Asakura M; Aki K; Fujimoto K; Shimizu K
Arch Immunol Ther Exp (Warsz); 2009; 57(3):189-98. PubMed ID: 19479202
[TBL] [Abstract][Full Text] [Related]
37. Molecular research in cancer: future clinical applications.
Ratliff TL
Acta Urol Belg; 1996 May; 64(2):53-5. PubMed ID: 8701813
[No Abstract] [Full Text] [Related]
38. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
39. Dendritic cells as therapeutic vaccines against cancer.
Banchereau J; Palucka AK
Nat Rev Immunol; 2005 Apr; 5(4):296-306. PubMed ID: 15803149
[TBL] [Abstract][Full Text] [Related]
40. Current immunotherapeutic strategies in prostate cancer.
Grosso JF; Drake CG
Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
